fda semaglutide warning september 2025 What Patients Need to Know About the GLP-1 Policy Changes Ivím Health Raises Alarm as

Satiety Signals: It enhances satiety signals in the brain, contributing to the feeling of fullness and aiding in controlling portion sizes and reducing overall food intake

Recognizing obesity as a medical condition rather than a cosmetic issue is essential to ensuring equitable access

This makes semaglutide a potentially powerful tool for weight management, particularly in individuals who struggle with obesity or have weight-related health conditions

Until these results are available, GLP-1 receptor agonists with established cardiovascular benefits (liraglutide, semaglutide, dulaglutide) are preferred by ADA guidelines for patients with established atherosclerotic cardiovascular disease

Qualification for semaglutide depends on the specific drug and its uses or indications approved by the US Food and Drug Administration (FDA)

The longer answer requires understanding several interconnected safety concerns